Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that ion-paired solutions significantly improved the skin penetration of risedronate in hairless mice compared to risedronate alone.

This review discusses the rationale for targeting 5α-reductase isoenzymes in prostate cancer prevention and treatment, highlighting the potential benefits of using inhibitors like dutasteride and finasteride but reports no new experimental results.

This review discusses the use of 5α-reductase inhibitors in treating benign prostatic hyperplasia, highlighting their long-term effectiveness and benefits when combined with α1-adrenergic antagonists; it reports no new clinical results.

Early balding may be a sign of future prostate problems.

This study found that lipid accumulation product (LAP) and free androgen index (FAI) can highly predict liver steatosis in women with PCOS phenotype A.

This review suggests that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have potential benefits for dermatologic conditions but may also cause adverse skin reactions and impact surgical outcomes.

This study concluded that dutasteride 0.5 mg/day improved hair growth in patients with androgenetic alopecia over six months but was associated with a higher prevalence of sexual dysfunction.

This study found that progesterone significantly delayed epileptogenesis development in a mouse model, and its effects were inhibited by finasteride, highlighting the potential role of neurosteroids in modifying epilepsy progression.

This meta-analysis found that treating male androgenetic alopecia with 5α-reductase inhibitors increases the risk of sexual dysfunction, with a statistically significant risk for finasteride but not for dutasteride.

This article reviews the potential of combining antiandrogenic and antiestrogenic treatments for BPH, highlighting aromatase inhibitors, but presents no new clinical results; further research is needed.

This article reviews treatment options for male androgenetic alopecia, including their distinct aims of arresting progression, stimulating regrowth, and concealing hair loss, and reports no new clinical results.

This article reviews the role and controversies of 5α-reductase inhibitors like finasteride and dutasteride in managing prostate cancer, without presenting new research results.

This review discusses polycystic ovary syndrome, highlighting its associations with hyperandrogenism, chronic anovulation, polycystic ovaries, and increased risks of infertility and metabolic disorders, and reports no new clinical results.

This genome-wide association study identified 20 genetic signals at 15 risk loci related to severe acne, revealing new insights into its genetic predisposition, particularly affecting skin structure and maintenance.

This congress summary highlights the COMEF 2023 event, which focused on medical ethics, education, and health through discussions with the theme "Learn, practice, excel," but reports no new research findings.

This article reviews the clinical assessment of female pattern hair loss and discusses up-to-date treatments, highlighting oral minoxidil combined with oral spironolactone as a promising novel therapy. It emphasizes the crucial role of general practitioners in diagnosis, treatment planning, and managing associated psychosocial issues.

Minoxidil is effective for hair growth and safe for long-term use.

This survey reported that 37.6% of male AGA patients were satisfied with their treatments, with the highest satisfaction for 5-alpha-reductase inhibitors, and revealed differing perceptions between physicians and patients about AGA's impact on confidence and treatment involvement.

The authors concluded that while finasteride 1 mg affects prostate-related pathways, evidence is insufficient to prove clinical benefits for prostate outcomes compared to the established effectiveness of finasteride 5 mg.

This study examined data from the FDA Adverse Event Reporting System and found that finasteride use is linked with both known and previously unlisted adverse events, such as erectile dysfunction and post-5α reductase inhibitor syndrome, with variations observed by age and sex.

5α-reductase inhibitors can reduce prostate cancer risk but may increase high-grade tumors, needing more research.

This study found that among women with polycystic ovary syndrome, higher age, obesity, hirsutism, and having children were independently associated with increased metabolic risk.

This review discusses significant developments in prostate cancer risk assessment, diagnosis, and treatment, but reports no new clinical results; the authors emphasize the evolving importance of prognostic factors and treatment implications.

Men with early balding may have a higher risk of prostate issues, and surgery for prostate cancer has a slight survival benefit over radiation.

This systematic review synthesizes evidence on the distribution of 5a-reductase isozymes and their implications for mental health, finding that inhibition of neurosteroidogenesis may contribute to anxiety, depression, and suicidality, with some patients experiencing persistent psychiatric effects from finasteride or dutasteride.

This study found that repeated oral intake of 0.5 or 5 mg/kg of cobalt ferrite nanoparticles induced pulmonary toxicity in rats, with dose-dependent oxidative stress and inflammation observed, but no notable toxicity was seen at a 0.05 mg/kg dose.

This study found that dutasteride effectively improved urinary symptoms, reduced acute urinary retention risk, and decreased prostate volume in men with moderate to severe BPH over two years.

This article discusses post-finasteride syndrome as a distinct syndrome related to prolonged use of 5α-steroid reductase inhibitors, noting persistent side effects even after discontinuation and no new research results are reported.

Finasteride helps improve hair growth in men with hair loss but may increase the risk of erectile dysfunction.

This review suggests that finasteride at 1 mg/day reduces PSA levels similarly to 5 mg/day, but differences in prostate dihydrotestosterone levels may affect prostate cancer diagnosis and prevention.